Rx-360 Announces the Release of the Rx-360 Supplier Assessment Questionnaire
Rx-360 has announced the release of the Rx-360 Supplier Assessment Questionnaire (SAQ). The SAQ was prepared by the Rx-360 Supplier-Led Working Group, an Rx-360 working group consisting of members from both pharmaceutical companies and leading suppliers to the pharmaceutical industry. Through this Working Group, members can share perspectives and work collaboratively to achieve greater harmonisation and efficiencies in the supply chain to better serve patients.
Pharmaceutical manufacturers and industry suppliers recognise the inefficiency and waste of resources when each individual pharmaceutical company creates its own supplier assessment questionnaire. Suppliers routinely exhaust valuable resources continuously completing slightly different forms of substantially similar questionnaires. To create the current Supplier Assessment Questionnaire, the Working Group analysed numerous sample questionnaires submitted by Rx-360 members. In addition to standardised content, document formatting and question completion was optimised for accuracy and ease of completion by suppliers.
The Rx-360 SAQ covers standard information that would be included in most supplier assessment questionnaires. The 4-part questionnaire is more detailed than most, but will decrease the number of times that questionnaires will need to be filled out by the supplier, while significantly decreasing the turn-around time back to manufacturers. The SAQ consists of four (4) modules:
• General Company Information
• Specific Site Information
• Product Supplier Appendix
• Services Supplier Appendix.
The Working Group believes the Rx-360 SAQ will create helpful efficiencies for both suppliers and pharmaceutical manufactures alike by
• Eliminating time-consuming redundancies
• Streamlining the process of approving suppliers
• Allowing comparative analysis of basic information.
The Supplier Led Working Group strongly encourages suppliers and manufacturers to consider adopting this SAQ in standard use. All modules will be available shortly for public download at the Rx-360 website.
The Supplier Led Working Group will be holding a public webinar to introduce the documents on 28 August 2014.
Anyone interested in learning more or considering use of the questionnaires is encouraged to attend. To RSVP, please register through this link: www4.gotomeeting.com/register/163722479.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.